NEWS & EVENTS

NEWS & EVENTS 

Agendia Collaborates with Prestigious Cancer Center, Institut Curie, for MammaPrint® BluePrint® 
Breast Cancer Kit Co-Validation Study
December 5, 2017

Institut Curie is one of an increasing number of major European cancer centers to become a co-validation partner for the new NGS-based MammaPrint BluePrint Kit.
View The Press Release
New Data at the San Antonio Breast Cancer Symposium Demonstrate the Value of MammaPrint® and BluePrint®Across Breast Cancer Patient Populations
November 30, 2017

IRVINE, CA, AMSTERDAM, NETHERLANDS – 30 November 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the presentation of extensive new data at the upcoming 2017 San Antonio Breast Cancer Symposium (SABCS), highlighting the value of its MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test and BluePrint® Breast Cancer Molecular Subtyping Test. A total of eleven posters and discussions are being presented at SABCS, which will take place at the Henry B. Gonzales Convention Center in San Antonio, Texas from December 5-9, 2017.

View The Press Release
NEW STUDY PUBLISHED IN JAMA ONCOLOGY SHOWS MAMMAPRINT® CHANGED BREAST CANCER TREATMENT DECISIONS IN 3 OUT OF 4 CASES WHERE GUIDANCE WAS UNCLEAR WITH THE 21-GENE ASSAY
October 20, 2017

Prospective PROMIS trial showed no correlation between the two tests highlighting potential under-and over-treatment risks throughout the 21-gene assay’s intermediate range.

Physicians changed their treatment decisions in approximately 34% of all cases and in 76% of cases where treatment decisions were discordant based on the indication of the MammaPrint test, with 79% of physicians having greater confidence in their recommendation with the added clarity of MammaPrint when the 21-gene assay yielded an intermediate result

Findings reinforce the recent ASCO Breast Cancer Guideline update which recommends the exclusive use of MammaPrint in clinically high risk and lymph node positive (1-3) patients

BUPA Global Insurance has a specific code (7331B) for the reimbursement of OncoSTRAT&GO
September 17, 2017

OncoDNA SA announces today that major health insurers, including BUPA Global Insurance, have approved reimbursement in the United Kingdom for its OncoSTRAT&GO test, to find the most appropriate treatment options for each appropriate cancer patient.
AGENDIA’S MAMMAPRINT® RECOMMENDED BY ASCO BREAST CANCER GUIDELINE IN FOCUSED UPDATE BASED ON LANDMARK MINDACT TRIAL DATA
July 10, 2017

ASCO® recommends MammaPrint® for clinical high risk, hormone receptor-positive, HER2-negative breast cancer, to inform decisions on withholding chemotherapy. ASCO recommends MammaPrint as currently the only genomic test to be used to guide treatment decisions for 1-3 lymph node positive early-stage breast cancer patients and marks the fourth positive international guideline update for MammaPrint in 2017, recognizing the highest level of clinical evidence provided by MINDACT.
View The Press Release
OncoDNA signs agreement with its Middle East distributor CryoGene
May 16, 2017

100 patients will benefit from personalized medicine based on the most comprehensive tumor profiling solution.
View The Press Release
Share by: